Author:
Zandieh Ali,Izad Maryam,Fakhri Mohammad,Amirifard Hamed,Khazaeipour Zahra,Harirchian Mohammad Hosein
Abstract
Abstract
Background
We aimed to evaluate the frequency of various types of B and T cells expressing CD21, CD32, and CD35 in multiple sclerosis (MS) clinical courses.
Methods
Peripheral blood mononuclear cell from 30 MS patients (17 relapsing remitting [RRMS], six secondary progressive [SPMS], and seven primary progressive MS [PPMS]) and 18 healthy subjects were analyzed. All patients were in acute attack. Healthy controls were matched for age and gender ratio. The frequencies of various subsets of B and T cells were determined using flow cytometry.
Results
The frequency of CD4+T cells was lower in MS patients compared to control subjects (41.14 ± 9.45% vs. 46.88 ± 6.98%, respectively, P < 0.05). The CD32+ fraction of CD4+T cells and the CD21+ fraction of CD8+T cells were higher in MS patients (2.85 ± 3.72% vs. 1.06 ± 0.62% for CD32+CD4+T cells, 2.71 ± 1.86% vs. 1.16 ± 0.99% for CD21+CD8+T cells in MS patients and control subjects, respectively, P < 0.05). After dividing subjects by type of MS course, higher values of these two T cell subsets were found in SPMS patients compared to control subjects (P < 0.05). Further, RRMS patients had lower levels of CD32+CD4+T cells than SPMS patients and also they had lower levels of CD32+CD8+T cells than PPMS patients (P < 0.05). However, neither the expression of CD35 on T cells nor the various B cell subsets were statistically different between the compared groups.
Conclusions
Our findings demonstrate that T cell subsets expressing CD21 and CD32 may differ with respect to the presence or clinical forms of MS disease. By contrast, CD35+T cells and different subsets of B cells are not altered in various MS clinical courses.
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Cognitive Neuroscience,Clinical Neurology
Reference37 articles.
1. Loma I, Heyman R: Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 2011, 9: 409-416. 10.2174/157015911796557911
2. Zwibel HL, Smrtka J: Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 2011, 17: 139-145. Suppl 5 Improving:S
3. Prescott JD, Factor S, Pill M, Levi GW: Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007, 13: 44-52.
4. Ramsaransing GS, De Keyser J: Benign course in multiple sclerosis: a review. Acta Neurol Scand 2006, 113: 359-369. 10.1111/j.1600-0404.2006.00637.x
5. Severson C, Hafler DA: T-cells in multiple sclerosis. Results Probl Cell Differ 2010, 51: 75-98.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献